BTIG initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $30 price target The firm views Maze as “an emerging leader in APOL1-mediated kidney disease,” arguing that MZE829 has “persuasive best-in-disease potential.” The firm expects Phase 1 proof of mechanism data for MZE782 before the end of September and then Phase 2 data from the HORIZON trial of MZE829 in Q1 of 2026, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics’ MZE782: Promising Potential in CKD Treatment Through SLC6A19 Inhibition
- Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health
- Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
- Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
- Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)